CION Ameerpet
Pancreatic Cancer · Neuroendocrine Tumours (PNET) · Reviewed by CION Oncologists
PNET grade and the Ki67 index — what your pathology report is telling you
A pancreatic neuroendocrine tumour report usually leads with a grade and a percentage, and almost nobody explains what either one is measuring. Grade describes how fast the tumour's cells are dividing — not how far the disease has spread, and not how unwell you are. This page explains where the number comes from, what each band means, and what it does and does not change.
- Grade is not stage — one describes how fast the cells divide, the other how far the disease has travelled.
- Two measurements set the grade — the mitotic count and the Ki67 proliferation index, both read off tissue.
- Well or poorly differentiated matters most — that word decides the pathway before the number does.
- A grade guides a plan — it does not describe one person's course, and it can differ between samples.
17+
Cancer Specialists
on Panel
on Panel
35+
Centres Across
Telangana & AP
Telangana & AP
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Start here
What “Grade” Means on a PNET Report
A pancreatic neuroendocrine tumour report almost always carries two things that are easy to confuse. The stage describes how far the disease has travelled — whether it is confined to the pancreas, involves nodes, or has reached the liver. The grade describes something completely different: how quickly the tumour's cells are dividing. Stage comes largely from scans. Grade comes only from looking at the tissue itself under a microscope. They can move independently of each other, and a small tumour can carry a high grade just as a large one can carry a low grade.
Grade is set from two measurements the pathologist makes on your tumour tissue. The first is the mitotic count — how many cells are caught in the act of dividing across a defined area of tumour. The second is the Ki67 proliferation index, which is what most reports lead with. Ki67 is a protein that sits in the nucleus of a cell only while that cell is actively cycling towards division; a resting cell does not carry it. The laboratory stains a slice of the tumour for that protein and counts the proportion of tumour nuclei that light up, usually in the busiest area of the sample. That proportion, written as a percentage, is your index.
The two measurements usually agree. Where they disagree, the higher of the two normally sets the grade, because the classification is deliberately cautious about under-calling a tumour. That is worth knowing if your report shows a modest mitotic count and a higher index, or the reverse — it is not a contradiction, and it does not mean one of the numbers is wrong.
The grade also sits inside a bigger decision that is made before the number is even reached. The current World Health Organization classification of neuroendocrine neoplasms first asks whether the tumour is well differentiated — still recognisably built like neuroendocrine tissue — or poorly differentiated. Well-differentiated tumours are called neuroendocrine tumours and are graded 1, 2 or 3. Poorly differentiated ones are called neuroendocrine carcinoma and travel a different pathway from the start. That split matters more than the number that follows it. Pancreatic neuroendocrine tumours explained sets out how this whole group differs from ordinary pancreatic adenocarcinoma.
Did you know? The World Health Organization classification of neuroendocrine neoplasms treats a well-differentiated grade 3 neuroendocrine tumour and a poorly differentiated neuroendocrine carcinoma as separate diagnoses, even though the two can carry a similar proliferation index. That separation was introduced precisely because the two were being managed as one thing and behaving as two, and NCCN guidance keeps them on distinct treatment pathways for the same reason. It is why the words well differentiated or poorly differentiated on your report carry as much weight as the percentage beside them — and why a report that gives an index without stating differentiation is an incomplete report worth querying before any plan is fixed.
The bands
The Grade Bands, and What Each One Usually Changes
These are the published classification bands, not outcome predictions. They describe how the tumour is behaving on the slide, and they shape how urgently and how intensively it is treated.
| What the report says | What the index usually shows | What it usually changes |
|---|---|---|
| Neuroendocrine tumour, grade 1 (well differentiated) | An index under 3%, alongside a low mitotic count. | Slow-dividing. Depending on size and site, the conversation is often about careful surveillance, an operation where the tumour can be removed cleanly, or somatostatin-analogue-class therapy — rather than about starting chemotherapy. |
| Neuroendocrine tumour, grade 2 (well differentiated) | An index of 3% to 20%. | The widest band, and the one where the plan is least predictable from the grade alone. Where you sit within the band, the tumour's size, spread and any hormone syndrome all matter as much as the label. |
| Neuroendocrine tumour, grade 3 (well differentiated) | An index above 20%, with the cells still organised like neuroendocrine tissue. | Still treated on the neuroendocrine tumour pathway, but more actively and with less watching. Systemic therapy usually starts sooner, and receptor imaging is still often useful. |
| Neuroendocrine carcinoma (poorly differentiated) | An index that is usually well above 20%, with the tissue architecture lost. | A different disease, not a worse version of the same one. It is managed on a chemotherapy-led pathway, decisions are made quickly, and receptor imaging is frequently unhelpful. |
Take this list to your appointment
What to Check on Your Own Report
- Does it say well differentiated or poorly differentiated? If that phrase is missing, the grade on its own cannot tell you which pathway you are on.
- Is a proliferation index actually given? A very small or crushed needle sample sometimes cannot support one, and the report will say so rather than guess.
- Is a mitotic count given as well, and do the two agree? If they disagree, ask which one the stated grade was taken from.
- Which specimen was it measured on? A needle biopsy samples one small part of the tumour; a removed specimen shows the whole of it. The grade can differ between them.
- Was the index counted in the busiest area? Neuroendocrine tumours are not uniform, and the convention is to report from the most active region found.
- Is the grade from the pancreas or from a deposit elsewhere? Grade can differ between the primary tumour and a secondary, and the difference changes the discussion.
- How old is the report? A grade measured a long time ago, or before treatment, may no longer describe how the tumour is behaving now.
If you are holding a report you cannot make sense of, bring it in rather than searching the number. Book a free consultation or call 1800 202 8726. We will read it with you line by line, including the parts that were never explained.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
A Grade Is a Measurement, Not a Forecast
It tells your team how fast the tumour is dividing. What happens next is decided with you.
What actually happens
How the Grade Is Turned Into a Plan
-
The report is read properly, and completed if it is thin
Differentiation, proliferation index, mitotic count, hormone staining and margins are checked as a set. Where something load-bearing is missing, we ask the reporting laboratory for it rather than working around the gap.
Reviewed in-house at CION; the laboratory is a partner service -
The grade is checked against the scans
A grade should match how the tumour is behaving on imaging. Pancreatic-protocol CT and MRI are ordered and reported by us; somatostatin-receptor PET and PET-CT, where the grade makes them useful, are arranged with partner nuclear-medicine centres.
CT and MRI in-house; receptor imaging coordinated -
The case goes to the tumour board
Grade, stage, hormone status and your general health are discussed together, with medical oncology, radiation oncology and the surgical partners in the room, before anything is committed to.
Tumour board at CION -
Systemic treatment is matched to the grade
Lower grades often call for somatostatin-analogue-class therapy or a period of structured observation; higher grades usually call for oral targeted therapy of the mTOR-inhibitor or TKI classes, or chemotherapy. Pancreatic cancer treatment in Hyderabad sets out the options in full.
Delivered in-house at CION, across 35+ centres -
Surgical and interventional steps are arranged with partners
The endoscopic ultrasound and biopsy that produced your grade, any pancreatic operation, stenting, staging laparoscopy and peptide receptor radionuclide therapy are booked with specialist centres. We tell you in advance where each one happens and who invoices you.
Coordinated with partner centres and may be billed there -
The grade is revisited if the behaviour changes
If the disease starts moving differently from what the grade predicted, a repeat sample is discussed rather than assumed unnecessary. What grade means for outlook is set out honestly in PNET prognosis and survival.
Reviewed in-house; re-biopsy coordinated
Plainly stated
What CION Delivers, and What Is Coordinated
Being clear about this early saves a difficult conversation later. Your first consultation is free and lasts 45 minutes, and it is a genuine review of your reports rather than a booking appointment. Bring the pathology report and the most recent scan report; between them they answer more of the grade question than anything you will read online.
Delivered in-house at CION, across 35+ centres in Telangana and Andhra Pradesh: reading and acting on the pathology report; tumour-board review of grade against imaging; systemic treatment for neuroendocrine tumours, including somatostatin-analogue-class therapy, oral targeted therapy of the mTOR-inhibitor and TKI classes, and chemotherapy where the grade calls for it; radiation where it has a role; the ordering and reporting of pancreatic-protocol CT, MRI and MRCP, and bloods; genetic counselling; nutrition and pancreatic enzyme replacement; pain relief, psycho-oncology and supportive care; and long-term follow-up.
Coordinated with specialist hepatobiliary, gastroenterology, endoscopy, pathology and nuclear-medicine partner centres, and may be billed there: endoscopic ultrasound with fine-needle biopsy and the laboratory that measures and reports the index; all pancreatic surgery; ERCP and biliary or duodenal stenting; staging laparoscopy; coeliac plexus block; PET-CT and somatostatin-receptor PET; and peptide receptor radionuclide therapy. We arrange these, we sit in on the decisions and we tell you in advance where each one happens. We do not describe them as our own theatre, endoscopy or laboratory lists, because they are not.
If you want the whole picture rather than this one page, the complete pancreatic cancer guide covers types, staging, treatment and cost in one place.
A grade tells your team how fast the tumour is dividing. It does not tell anyone how your own course will run, and nobody should convert it into a timeline for you. Book a free consultation or call 1800 202 8726.
Take the next step
Understand the Report Before the Plan
Treatment is far easier to carry when you know what the words and numbers on the page actually describe.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
PNET grade and Ki67 — your questions answered
What does the Ki67 index actually measure?
Ki67 is a protein that appears in the nucleus of a cell only while that cell is actively cycling towards division. A resting cell does not carry it. The laboratory stains a slice of your tumour for that protein and counts the proportion of tumour cell nuclei that take up the stain, conventionally in the busiest area of the sample. That proportion, written as a percentage, is the proliferation index. It is a direct measure of how much of the tumour was dividing at the moment the sample was taken. It is not a measure of size, of spread, or of how unwell you are, and it is not a score out of anything. It is one of the two measurements that set the grade, the other being the mitotic count.
Is a higher index always worse news?
A higher index does mean a faster-dividing tumour, and grade is one of the things that shapes how urgently and how intensively a neuroendocrine tumour is treated. But it is one input among several rather than a verdict. Size, whether the tumour is confined to the pancreas, whether it is producing a hormone, how it looks on receptor imaging and your own general health all feed into the plan alongside it. Faster-dividing tumours are also often the ones that respond more visibly to systemic treatment, which is why a higher grade frequently changes the order of treatment rather than closing options down. What a grade cannot do is describe an individual course, and anyone converting your index into a personal timeline is going well beyond what the measurement supports.
My biopsy gave one grade and the surgical specimen gave another. Why?
This is common, and it usually reflects sampling rather than an error. A needle biopsy takes a very small amount of tissue from one part of the tumour, while a removed specimen gives the pathologist the whole thing to look at. Neuroendocrine tumours are not uniform: one region can be dividing faster than another, and the convention is to report the index from the most active region found. If the needle happened to miss that region, the grade rises when the full specimen is examined. Grade can also genuinely change over time in a tumour that has been present for years or has been treated. The grade from the larger, more representative specimen is generally the one used for planning, and it is worth asking your team which report their plan is built on.
What is the difference between a grade 3 tumour and a neuroendocrine carcinoma?
They can carry a similar proliferation index and are still handled as different diseases. A grade 3 neuroendocrine tumour is well differentiated: under the microscope the cells are still organised like neuroendocrine tissue, they often still carry somatostatin receptors, and they behave like the lower grades, only faster. A neuroendocrine carcinoma is poorly differentiated: the architecture is lost, receptor imaging is frequently unhelpful, and the disease typically moves quickly and is managed on a chemotherapy-led pathway from the outset. The distinction is made by the pathologist on how the cells look, not by the number alone. If your report gives a high index without saying which of the two it is, ask, because the answer changes the entire pathway.
Does the grade decide whether I need surgery?
Not on its own. Whether an operation is the right move depends mainly on where the tumour sits, how big it is, whether it can be removed completely and safely, whether it has spread, and how well you would come through a pancreatic operation. Grade informs that conversation - a slow, low-grade tumour may be watched or treated systemically rather than operated on, and a fast one may need systemic treatment first - but it is not the deciding factor by itself. All pancreatic surgery, and the endoscopic ultrasound and biopsy that produced your grade in the first place, are coordinated with specialist partner centres and may be billed there. The oncology plan around the operation is run by us.
What does CION do about the grade, and what happens at the first visit?
Bring the pathology report and the most recent scan report. The first consultation is free and lasts 45 minutes. We read the report with you, confirm whether the tumour is described as well or poorly differentiated, check that both a proliferation index and a mitotic count are present, and say plainly whether the grade in front of you is the one your plan should be built on. Systemic treatment for neuroendocrine tumours, radiation where it has a role, imaging and bloods, genetic counselling, nutrition and enzyme support and supportive care are delivered by CION across 35+ centres. Endoscopic ultrasound and biopsy, the reporting laboratory, all pancreatic surgery, receptor imaging and peptide receptor radionuclide therapy are coordinated with specialist partner centres and may be billed there.
Medical disclaimer: This page explains what grade and the Ki67 proliferation index describe on a pancreatic neuroendocrine tumour pathology report and how they are used in planning, and is reviewed by a CION medical oncologist with reference to NCCN guidance and the World Health Organization classification of neuroendocrine neoplasms. It is general information and not a substitute for an individual pathological or oncological opinion; what your own grade means depends on your tumour type, stage, hormone status, imaging and general health, and must be decided with your treating team. No survival figure is stated here because a grade describes a group of tumours and not one person's course. Reading and acting on the report, tumour-board review, systemic therapy for neuroendocrine tumours of the classes described, radiation, pancreatic-protocol CT, MRI and MRCP and bloods, genetic counselling, nutrition and pancreatic enzyme support, pain and psycho-oncology care and survivorship follow-up are delivered by CION. Endoscopic ultrasound and biopsy, the histopathology laboratory that measures and reports the index, all pancreatic surgery, ERCP and biliary or duodenal stenting, staging laparoscopy, coeliac plexus block, PET-CT, somatostatin-receptor PET and peptide receptor radionuclide therapy are coordinated with specialist hepatobiliary, gastroenterology, endoscopy, pathology and nuclear-medicine partner centres and may be billed there.